Korea BNC is showing an upward trend following news of the development of an oral COVID-19 treatment.
Korea BNC announced that it has applied for and obtained emergency approval for the use of its new COVID-19 treatment candidate substance, ‘Antroquinonol,’ for treating COVID-19 infected patients.
So, what will be the next COVID-19 treatment stock to surge? The unprecedented COVID-19 pandemic is acting as an opportunity for stock investment. While almost all stocks rose last year, this year the stock prices are moving according to themes, creating a typical thematic stock market. Analysis of themes and stocks has become crucial.
Large-cap stocks that led the market last year are stuck in a box range, but the KOSPI and KOSDAQ indices continue to trend upward, so it is still too early to leave the stock market.
This is a difficult market where theme and stock analysis bring profits rather than economic fundamentals. Investing alone in such a market is quite risky. Following the rapidly changing market late with ‘lagging investment’ often leads to worrying alone while others make profits.
Let’s focus on YC Investment Group, which is achieving great results in the thematic stock market. How about sharing their investment know-how, which is based on fairness and transparency and shows high trust and performance? Receive a customized total solution for individual investors covering growth value stocks, day trading/swing trading, and themes/issues, and become a leader in the stock market.
▶ Become a shining leader in this challenging stock market! Apply for YC Investment Group free trial
Interested stock codes: Jinwon Life Sciences / Seorin Bio / SM Life Design / IA / AD Chips
※ This content is unrelated to the editorial direction of Asia Economy, and all responsibility lies with the information provider.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
